These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35801613)

  • 21. Neuropsychiatric effects of Parkinson's disease treatment.
    Aarons S; Peisah C; Wijeratne C
    Australas J Ageing; 2012 Sep; 31(3):198-202. PubMed ID: 22950594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy.
    Hinnell C; Hulse N; Martin A; Samuel M
    Parkinsonism Relat Disord; 2011 May; 17(4):295-6. PubMed ID: 21300562
    [No Abstract]   [Full Text] [Related]  

  • 24. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review.
    Nakum S; Cavanna AE
    Parkinsonism Relat Disord; 2016 Apr; 25():10-6. PubMed ID: 26923525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework.
    Okai D; Samuel M; Askey-Jones S; David AS; Brown RG
    Eur J Neurol; 2011 Dec; 18(12):1379-83. PubMed ID: 21615625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
    Trifirò G; Mokhles MM; Dieleman JP; van Soest EM; Verhamme K; Mazzaglia G; Herings R; de Luise C; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; van Camp G; Zanettini R; Sturkenboom MC
    Drug Saf; 2012 Feb; 35(2):159-71. PubMed ID: 22204718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease.
    Choi JH; Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho JW
    Neurodegener Dis; 2019; 19(5-6):171-177. PubMed ID: 32454490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.
    Kon T; Ueno T; Haga R; Tomiyama M
    Brain Behav; 2018 Aug; 8(8):e01036. PubMed ID: 29956879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impulse control disorders in Parkinson's disease: a psychosocial perspective.
    Delaney M; Leroi I; Simpson J; Overton PG
    J Clin Psychol Med Settings; 2012 Sep; 19(3):338-46. PubMed ID: 22581074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.
    Driver-Dunckley E; Samanta J; Stacy M
    Neurology; 2003 Aug; 61(3):422-3. PubMed ID: 12913220
    [No Abstract]   [Full Text] [Related]  

  • 33. Suicide without depression after withdrawal of a dopamine agonist in a patient with Parkinson's disease.
    Flament M; Loas G; Godefroy O; Krystkowiak P
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E32. PubMed ID: 22231340
    [No Abstract]   [Full Text] [Related]  

  • 34. Impulse control disorders in Parkinson's disease.
    Weintraub D; Potenza MN
    Curr Neurol Neurosci Rep; 2006 Jul; 6(4):302-6. PubMed ID: 16822350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.
    Stocchi F; Fossati B; Torti M
    Expert Opin Drug Saf; 2020 Sep; 19(9):1155-1172. PubMed ID: 32869676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced compulsive behaviors: exceptions to the rule.
    Graham NA; Hammond CJ; Gold MS
    Mayo Clin Proc; 2009 Sep; 84(9):846-7; author reply 847. PubMed ID: 19720785
    [No Abstract]   [Full Text] [Related]  

  • 37. [Impulse control disorders associated with dopaminergic agonists in Parkinson's disease. Case report].
    Gamboa Arango A; Bernal Bernal MT; Duaso Magaña E
    Rev Esp Geriatr Gerontol; 2016; 51(5):304-5. PubMed ID: 27016028
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on rotigotine in Parkinson's disease.
    Baldwin CM; Keating GM
    Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine agonists and risk: impulse control disorders in Parkinson's disease.
    Voon V; Gao J; Brezing C; Symmonds M; Ekanayake V; Fernandez H; Dolan RJ; Hallett M
    Brain; 2011 May; 134(Pt 5):1438-46. PubMed ID: 21596771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.